Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer
- PMID: 24156927
- DOI: 10.1016/j.maturitas.2013.09.012
Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer
Abstract
Background: Mutations in brca1 and 2 genes lead to a significant increase in the lifetime risk of developing breast (BC) and ovarian cancer (OC). There are indications that birth cohort can influence the cancer risk in brca1 mutation carriers. Therefore, we investigated the risks for BC and OC associated with brca2 mutations in a cohort of female mutation carriers of a genetically heterogeneous Central European population.
Patients and methods: This study included 246 women in whom a functional mutation in the brca2 gene had been identified at our institution. At the time of analysis, 153 women had developed cancer (142 BC, 9 OC, 2 BC and OC). Risks were estimated using the product limit method. The log rank test was used to compare different strata.
Results: After correction for risk-reducing surgeries, the cumulative risk of developing cancer to age 70 was found to be 88% for BC (95% CI 81-95%) and 31% for OC (95% CI 17-45%). Female brca2 mutation carriers born in 1958 or later were at a significantly higher risk of developing BC at a younger age (p<0.001), while no such age cohort-dependent correlation was found for OC.
Conclusion: The age cohort-dependent early onset in BC in women born after 1958 strongly suggests the importance of exogenous factors such as lifestyle modification while this does not seem to be the case for OC. Female brca2 mutation carriers should be counseled about their age cohort-dependent breast cancer risk.
Keywords: BRCA2; Breast cancer risk; Hereditary breast and ovarian cancer; Penetrance of BRCA2.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.J Clin Oncol. 2015 Aug 10;33(23):2553-62. doi: 10.1200/JCO.2014.59.0463. Epub 2015 Jul 6. J Clin Oncol. 2015. PMID: 26150446 Free PMC article. Review.
-
Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.Hum Mutat. 2005 Dec;26(6):583-9. doi: 10.1002/humu.20261. Hum Mutat. 2005. PMID: 16287141
-
Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.Breast Cancer Res Treat. 2011 Sep;129(2):557-63. doi: 10.1007/s10549-011-1509-z. Epub 2011 Apr 16. Breast Cancer Res Treat. 2011. PMID: 21499684
-
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4. Breast Cancer Res Treat. 2010. PMID: 20204502
-
[Clinical and molecular diagnosis of inherited breast-ovarian cancer].J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. J Gynecol Obstet Biol Reprod (Paris). 2003. PMID: 12717301 Review. French.
Cited by
-
Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.BMC Cancer. 2023 Apr 13;23(1):339. doi: 10.1186/s12885-023-10822-5. BMC Cancer. 2023. PMID: 37055759 Free PMC article.
-
Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation.Genome Med. 2017 Feb 6;9(1):13. doi: 10.1186/s13073-017-0403-7. Genome Med. 2017. PMID: 28166811 Free PMC article.
-
Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly.BMC Med Genomics. 2016 Feb 4;9:7. doi: 10.1186/s12920-016-0167-8. BMC Med Genomics. 2016. PMID: 26846091 Free PMC article.
-
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.J Clin Oncol. 2015 Aug 10;33(23):2553-62. doi: 10.1200/JCO.2014.59.0463. Epub 2015 Jul 6. J Clin Oncol. 2015. PMID: 26150446 Free PMC article. Review.
-
The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome.Genes (Basel). 2021 Sep 24;12(10):1483. doi: 10.3390/genes12101483. Genes (Basel). 2021. PMID: 34680878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous